Affiliations

  • PMID: 18830927

Review

Diamyd, an alum-formulated recombinant human GAD65 for the prevention of autoimmune diabetes

Simon A Hinke. Curr Opin Mol Ther. 2008 Oct.

Abstract

Diamyd Medical AB is developing Diamyd (GAD-65), an alum formulation of a full-length recombinant human glutamic acid decarboxylase 65 for subcutaneous injection, for the potential prevention and treatment of type 1 diabetes (T1DM) or latent autoimmune diabetes (LADA) in adults. Phase II clinical trials indicated that Diamyd was safe and well tolerated in patients with T1DM or LADA. Diamyd is currently in phase II/III and III clinical trials for T1DM.

Similar articles

Cited by 5 articles

Publication types

MeSH terms

Substances

Write us

Find us at the office

Darmofal- Broderick street no. 11, 88736 Vatican City, Vatican City

Give us a ring

Meadow Hipsley
+90 293 316 242
Mon - Fri, 8:00-14:00

Join us